These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


207 related items for PubMed ID: 12766998

  • 1. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
    Shaw ML, McLauchlan J, Mills PR, Patel AH, McCruden EA.
    J Med Virol; 2003 Jul; 70(3):361-72. PubMed ID: 12766998
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
    Hofmann WP, Sarrazin C, Kronenberger B, Schönberger B, Bruch K, Zeuzem S.
    J Infect Dis; 2003 Mar 15; 187(6):982-7. PubMed ID: 12660945
    [Abstract] [Full Text] [Related]

  • 5. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.
    Kronenberger B, Sarrazin C, Hofmann WP, von Wagner M, Herrmann E, Welsch C, Elez R, Rüster B, Piiper A, Zeuzem S.
    J Viral Hepat; 2004 Jul 15; 11(4):310-8. PubMed ID: 15230853
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.
    Am J Gastroenterol; 2003 Jun 15; 98(6):1377-83. PubMed ID: 12818284
    [Abstract] [Full Text] [Related]

  • 8. Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity.
    Chan-Fook C, Jiang WR, Clarke BE, Zitzmann N, Maidens C, McKeating JA, Jones IM.
    Virology; 2000 Jul 20; 273(1):60-6. PubMed ID: 10891408
    [Abstract] [Full Text] [Related]

  • 9. Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.
    Hamed MR, Tarr AW, McClure CP, Ball JK, Hickling TP, Irving WL.
    J Viral Hepat; 2008 May 20; 15(5):339-45. PubMed ID: 18221305
    [Abstract] [Full Text] [Related]

  • 10. Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.
    McCaffrey K, Boo I, Poumbourios P, Drummer HE.
    J Virol; 2007 Sep 20; 81(17):9584-90. PubMed ID: 17581991
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
    Allander T, Forns X, Emerson SU, Purcell RH, Bukh J.
    Virology; 2000 Nov 25; 277(2):358-67. PubMed ID: 11080483
    [Abstract] [Full Text] [Related]

  • 12. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface.
    Forns X, Allander T, Rohwer-Nutter P, Bukh J.
    Virology; 2000 Aug 15; 274(1):75-85. PubMed ID: 10936090
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hepatitis C virus envelope glycoproteins complementation patterns and the role of the ecto- and transmembrane domains.
    Lin X, Zhang Y, Bi S, Lu J, Zhao H, Tan W, Li D, Wang Y.
    Biochem Biophys Res Commun; 2009 Jul 24; 385(2):257-62. PubMed ID: 19464265
    [Abstract] [Full Text] [Related]

  • 15. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles.
    Lee IH, Kim CH, Ryu WS.
    J Med Virol; 1996 Oct 24; 50(2):145-51. PubMed ID: 8915880
    [Abstract] [Full Text] [Related]

  • 16. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
    Schofield DJ, Bartosch B, Shimizu YK, Allander T, Alter HJ, Emerson SU, Cosset FL, Purcell RH.
    Hepatology; 2005 Nov 24; 42(5):1055-62. PubMed ID: 16250048
    [Abstract] [Full Text] [Related]

  • 17. Evidence for a polytopic form of the E1 envelope glycoprotein of Hepatitis C virus.
    Migliaccio CT, Follis KE, Matsuura Y, Nunberg JH.
    Virus Res; 2004 Sep 15; 105(1):47-57. PubMed ID: 15325080
    [Abstract] [Full Text] [Related]

  • 18. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.
    Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J.
    Proc Natl Acad Sci U S A; 2008 Jan 22; 105(3):997-1002. PubMed ID: 18195353
    [Abstract] [Full Text] [Related]

  • 19. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.
    Drummer HE, Boo I, Maerz AL, Poumbourios P.
    J Virol; 2006 Aug 22; 80(16):7844-53. PubMed ID: 16873241
    [Abstract] [Full Text] [Related]

  • 20. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH.
    Proc Natl Acad Sci U S A; 2003 Nov 25; 100(24):14199-204. PubMed ID: 14617769
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.